Pharma Co.'s Partnership a Key Validation
Source: Dr. Robert Driscoll  (12/4/23)
Recently, Arcus Biosciences Inc. announced a partnership with Exelixis Inc., which may be the key to validating the company, noted WedBush analysts in a December 4 report. More >

Biotech Announces New Responder in Breast Cancer Trail
Source: Emily Bodnar  (11/30/23)
Recently, BriaCell Therapeutics Corp. announced a new exceptional responder in its Phase 2 study evaluating the company's off-the-shelf personalized immunotherapy, noted H.C. Wainwright analyst Emily Bodnar. More >

Biotech Receives First Approval; Drug Now Available
Source: Robert Burns  (11/28/23)
Recently, SpringWorks Therapeutics Inc. announced FDA approval of OGSIVEO (nirogacestat) for treating progressing desmoid tumors (DT) in adult patients based on Phase 3 DeFi trial results, noted H.C. Wainwright & Co. analysts Robert Burns and Dr. Raghuram Selvaraju. More >

Encouraging Early Data For Biotech's Cancer Therapies
Source: Emily Bodnar  (11/21/23)
In a recent corporate update, Purple Biotech Ltd. reported positive interim Phase 1/2 data for NT219 and accelerated enrollment for CM24, noted H.C. Wainwright analyst Emily Bodnar. More >

Strong Early Launch Metrics for Biotech's Skin Disease Drug
Source: Oren Livnat  (11/20/23)
Oren Livnat of H.C. Wainwright & Co. sees over 240% upside potential for Verrica Pharmaceuticals based on the early commercial success of its recently launched skin disease treatment. More >

Arizona Biotech Advances Multiple Cell Therapies
Source: Dr. Jonathan Aschoff  (11/16/23)
Roth MKM has a US$30 price target on this biotech company based on progress across its regenerative medicine pipeline, including upcoming Phase 1/2 data. More >

Massachusetts Biotech Advances Novel Cytokine Therapies
Source: Dr. Robert Driscoll  (11/15/23)
Wedbush sees over 300% upside for Werewolf stock based on early clinical success for its PREDATOR platform and pipeline, according to a WedBush research note. More >

Massachusetts Biotech Presents Catalysts Into 2024
Source: Dr. David Nierengarten  (11/8/23)
Cambridge, Massachusetts-based iTeos Therapeutics presented multiple upcoming catalysts into 2024 after reporting Q3 results, noted Wedbush analyst Dr. David Nierengarten. More >

Texas Biotech Exceeds Alzheimer's Trial Enrollment Target
Source: Vernon Bernardino  (11/8/23)
This Texas-based biotech company's enrollment in its two pivotal Phase 3 trials evaluating lead drug candidate simufilam for Alzheimer's disease surpassed initial enrollment targets, noted H.C. Wainwright analyst Vernon Bernardino. More >

Expert Shares Thoughts on Six Stocks
Source: Chris Temple  (11/7/23)
Chris Temple of The National Investors shares a detailed report on stocks from the life science to the energy sector to tell you which he believes are Buys and which you should sell. More >

Biopharma Acquires Royalty on Approved Diabetes Drug
Source: Dr. Joseph Pantginis  (11/3/23)
This is one of the California-based company's many transactions resulting from its royalty monetization strategy, noted an H.C. Wainwright & Co. report. More >

Survey Results Positive for New HAE Drug
Source: Hartaj Singh  (11/2/23)
Most responding physicians, all with hereditary angioedema patients, indicated an "above average" impression of the treatment's safety and efficacy data, noted an Oppenheimer report. More >

Safety Profile of New IL-2 Molecule Better Than Like Drugs'
Source: Andres Maldonado  (11/2/23)
First clinical data of this investigational interleukin-2 cytokine show it lacks the degree and rates of adverse events typically seen with treatments of this kind, noted an H.C. Wainwright & Co. report. More >

Firm To Present Trial Results Update at SITC Meeting
Source: Dr. David Nierengarten  (11/2/23)
Data will be reviewed from Part B, the dose expansion portion, of the Phase 1 study of a new TGF-β1 isoform inhibitor in advanced cancer, noted a Wedbush report. More >

Add Back Positions in This Biotech
Source: Chris Temple  (11/1/23)
Chris Temple of The National Investor shares one stock he believes is currently a Buy, as a gross overreaction caused sell-offs. More >

Biotech to Advance New Type 1 Diabetes Drug Into Clinic
Source: Edward White  (10/23/23)
Dosing of the first patient is expected in Q4/23 in this Phase 1 trial to be done in Australia, noted an H.C. Wainwright & Co. report. More >

Approval Likely in U.S., EU for New Drug for Prader-Willi
Source: Dr. Leland Gershell  (10/12/23)
Despite recent positive clinical trials, the biopharma behind this treatment remains undervalued presenting a buying opportunity, noted an Oppenheimer report. More >

Drug Reform Streaming Co. Starts Trading on CSE
Source: Streetwise Reports  (10/12/23)
This company investing in and incubating companies at the forefront of drug policy reform has started trading on the Canadian Securities Exchange. One writer says buying stock is a chance to be a part of a "movement." More >

Diagnostics Biotech Beats Revenue Estimates in Q3/23
Source: Francois Brisebois  (10/11/23)
The Belgium-based company is well on its way to achieving, and possibly exceeding, full-year revenue guidance, noted an Oppenheimer report. More >

Chen Still Likes This Precious Metal in Q4
Source: Streetwise Reports  (10/9/23)
If you've been following asset manager Chen Lin's quarterly picks on Streetwise Reports, you know he is bullish on one particular precious metal, and the fourth quarter of 2023 is no exception. More >

Trial of New Drug for Acute Leukemia Meets Primary Endpoint
Source: Edward White  (10/5/23)
The biopharma behind it plans to submit a new drug application, seeking approval of the compound, by year-end, noted an H.C. Wainwright & Co. report. More >

New CAR-T Therapy Shows Potency in Certain Patients
Source: Dr. Jonathan Aschoff  (10/4/23)
Study results for patients with relapsed/refractory multiple myeloma continue to be "favorable," noted a ROTH Capital Partners report. More >

New Contract Adding Thousands of Patients to Telehealth Platform
Source: Streetwise Reports  (9/27/23)
This telehealth company has signed a contract with a physician network to add as many as 100,000 patients to its platform. Find out why the CEO says it is in a period of rapid growth. More >

Biopharma Co. Adds CTO to Team
Source: Francois Brisebois  (9/21/23)
This newest member brings with him extensive experience in protein development and manufacturing, noted an Oppenheimer report. More >

Trial Results Validate New Drug-Delivering Nasal Implant
Source: Matthew Caufield  (9/20/23)
This product candidate presents a compelling approach to treating post-surgery chronic rhinosinusitis patients, noted an H.C. Wainwright & Co. report. More >